EMA Pharmacovigilance Legislation to Take Effect; New Q&A Document Offers Practical Guidance to Industry

News
Article

In July 2012, new pharmacovigilance legislation will come into effect across the EU as a result of changes adopted in 2010, specifically EU Regulation No. 1235 and Directive 84.

In July 2012, new pharmacovigilance legislation will come into effect across the EU as a result of changes adopted in 2010, specifically EU Regulation No. 1235 and Directive 84. Information that marketing authorization holders provide to EMA and other regulatory authorities about their pharmacovigilance systems will change according to advice from the Medicines and Healthcare Regulatory Agency (MHRA) as follows:

  • Only a summary of information pertaining to the EU qualified person for pharmacovigilance and the location of a pharmacovigilance system master file will need to be noted in marketing authorizations.

  • Full descriptive information about the pharmacovigilance system will have to be contained in a pharmacovigilance system master file, which should be made available to the National Competent Authorities upon request.

  • Detailed requirements for the pharmacovigilance system master file include its availability, structure, content and maintenance.

  • The pharmacovigilance system master file will need to encompass the pharmacovigilance system. The system, therefore, may relate to one or more products, and changes to its content will not be automatically notifiable to the Competent Authorities.

The full guideline can be accessed here.

The submission information noted above is different from the current Detailed Description of the Pharmacovigilance system (DDPS), which will be phased out over the period from July 2012–2015.

On May 23, 2012, EMA published a set of Question and Answers covering a number of topics related to the legislation. The document explains some practical considerations that the industry will need to consider. Specifically, the Q&A document provides guidelines on:

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.